Chardan Capital Issues Optimistic Estimate for TNYA Earnings

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Equities researchers at Chardan Capital increased their FY2025 earnings estimates for Tenaya Therapeutics in a research report issued to clients and investors on Monday, March 24th. Chardan Capital analyst Y. Livshits now forecasts that the company will post earnings of ($0.71) per share for the year, up from their prior forecast of ($1.10). Chardan Capital currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its earnings results on Monday, March 17th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04.

A number of other research firms also recently issued reports on TNYA. Canaccord Genuity Group cut their price target on Tenaya Therapeutics from $18.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday, March 13th. Morgan Stanley reduced their target price on shares of Tenaya Therapeutics from $15.00 to $5.00 and set an “overweight” rating for the company in a report on Wednesday, March 12th. Finally, HC Wainwright dropped their price target on shares of Tenaya Therapeutics from $18.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, March 11th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $6.25.

Tenaya Therapeutics Stock Performance

Tenaya Therapeutics stock opened at $0.64 on Thursday. Tenaya Therapeutics has a one year low of $0.39 and a one year high of $5.25. The stock has a fifty day moving average of $0.90 and a 200 day moving average of $1.69. The stock has a market cap of $56.26 million, a PE ratio of -0.45 and a beta of 2.83.

Hedge Funds Weigh In On Tenaya Therapeutics

Several large investors have recently made changes to their positions in the business. JPMorgan Chase & Co. grew its position in shares of Tenaya Therapeutics by 20,670.3% during the fourth quarter. JPMorgan Chase & Co. now owns 5,155,596 shares of the company’s stock worth $7,373,000 after purchasing an additional 5,130,774 shares in the last quarter. Trustees of Columbia University in the City of New York purchased a new stake in Tenaya Therapeutics during the 4th quarter valued at approximately $417,000. Jacobs Levy Equity Management Inc. raised its position in shares of Tenaya Therapeutics by 204.4% during the third quarter. Jacobs Levy Equity Management Inc. now owns 337,265 shares of the company’s stock valued at $651,000 after buying an additional 226,466 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Tenaya Therapeutics in the fourth quarter worth $150,000. Finally, Deutsche Bank AG boosted its position in shares of Tenaya Therapeutics by 304.1% during the fourth quarter. Deutsche Bank AG now owns 129,319 shares of the company’s stock worth $185,000 after acquiring an additional 97,318 shares during the last quarter. 90.54% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, major shareholder Group Gp Lp Column III bought 35,714,284 shares of the company’s stock in a transaction that occurred on Wednesday, March 5th. The stock was bought at an average price of $0.70 per share, with a total value of $24,999,998.80. Following the acquisition, the insider now owns 49,313,559 shares of the company’s stock, valued at approximately $34,519,491.30. This represents a 262.62 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders have sold 19,621 shares of company stock worth $10,595. Company insiders own 32.76% of the company’s stock.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.